Altimmune, Inc.
ALT
$3.42
$0.000.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 420.00% | 0.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 420.00% | 0.00% | |||
| Cost of Revenue | 23.05% | -13.20% | |||
| Gross Profit | -22.92% | 13.21% | |||
| SG&A Expenses | 78.01% | 3.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 38.61% | -9.00% | |||
| Operating Income | -38.52% | 9.00% | |||
| Income Before Tax | -43.88% | 14.14% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -43.88% | 14.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -43.88% | 14.14% | |||
| EBIT | -38.52% | 9.00% | |||
| EBITDA | -38.57% | 9.00% | |||
| EPS Basic | -27.89% | 21.78% | |||
| Normalized Basic EPS | -27.84% | 21.78% | |||
| EPS Diluted | -27.89% | 21.78% | |||
| Normalized Diluted EPS | -27.84% | 21.78% | |||
| Average Basic Shares Outstanding | 12.52% | 9.75% | |||
| Average Diluted Shares Outstanding | 12.52% | 9.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||